Ross, K.; Harrison, R.F.; Jankowski, J.
April 2003
Gut;Apr2003 Supplement 1, Vol. 52, pA47
Academic Journal
Background: During tumour formation, the tissue-specific isoenzymes of pyruvate kinase (PK), such as bPK in liver and M1-PK in muscle and brain are lost and M2-PK is expressed. The dimeric form of M2-PK is specifically expressed by a wide range of different tumour cells, including those of the gastrointestinal tract, pancreas, kidney, breast, lung, and prostate. This study aimes to characterize the expression of M2-PK in the progression of Barrett's oesophagus to adenocarcinoma. Material and Methods: Oesophageal biopsies from 113 patients: 17 reflux oesophagitis, 37 intestinal metaplasia oF the oesophagus, 21 Barrett's high grade dysplasia and 38 Barrett's adenocarcinoma were stained and semiquantified using monoclonal mouse anti-human antibodies against dimeric M2-PK. Staining was assessed with regard to location and intensity and the proportion of cells staining. Results: All cases of reflux oesophagitis showed positive staining in the basal layers of the squomous epithelium, where the cells are immature and proliferating. All cases of Barrett's metaplasia stained positively but staining was very variable from <30% of cells to 100% of cells. The majority of cases of Barrett's dysplasia showed widespread positive staining in dysplastic ceils, but also some negative areas. All adenocarcinomas cases were strongly positive for M2-PK antibody. Conclusion: The results of this study have shown inappropriate expression of M2-PK in neoplastic Barrett's mucosa. There was an increase of M2-PK expression as the Barrett's metaplasia-dysplasiaadenocarcinoma sequence progressed.


Related Articles

  • Study of pyruvate kinase activity in human astrocytomas – Alanine-inhibition test revisted. Javalkar, V. K.; Vinod, K. Y.; Sharada, S.; Chandramouli, B. A.; Subhash, M. N.; Kolluri, V. R. // Neurology India;Mar2009, Vol. 57 Issue 2, p140 

    Background: Recent studies have confirmed that alterations in the isoenzyme of pyruvate kinase (PK) provide tumor cells with selective growth advantage. Aims: Our aim was to establish the mean activity of the enzyme PK in human astrocytomas and to look for any trends in the activity with...

  • PKM2: A gatekeeper between growth and survival. Harris, Isaac; McCracken, Susan; Mak, Tak Wah // Cell Research;Mar2012, Vol. 22 Issue 3, p447 

    The article discusses the association of pyruvate kinase isoenzyme type M2 (PKM2) with p-Tyr peptides in beta-catenin to drive c-Myc and cyclin D1 (CCND1) expression in addition to the effect of PKM2 on the control of anabolic growth. It notes the potential of the availability of PKM2 to link...

  • Pirüvat Kinazın Normal ve Tümör Meme Dokusundan SaflaÅŸtırılması ve Karakterizasyonu. Yilmaz, Seval; Ozan, Sema Temizer; Özercan, Ibrahim Hanifi // Turkish Journal of Veterinary & Animal Sciences;2004, Vol. 28 Issue 6, p1087 

    The molecular weight and kinetic properties of pyruvate kinase purified from human normal and tumor breast tissues were studied and the activity levels of pyruvate kinase from normal and tumor breast tissues were compared. The presence of 2 forms of pyruvate kinase in human breast tissue was...

  • COMPARISON OF GLYCOLYTIC ENZYME AND ISOENZYME ACTIVITY IN BREAST CANCERS AND DYSPLASIA. Katić, Katica Bajin // Medicinski Pregled / Medical Review;May/Jun2012, Vol. 65 Issue 5/6, p200 

    The study was aimed at assessing the total enzyme activity and the profile of breast cancer and dysplasia on the human material. In addition, the validity of data was evaluated from the aspect of improving diagnostics. Lactate dehydrogenase activity, as well as the profile of its isoenzymes,...

  • Evolution of C4 phosphoenolpyruvate carboxylase in the genus Alternanthera: gene families and the enzymatic characteristics of the C4 isozyme and its orthologues in C3 and C3/C4 Alternantheras. Gowik, U.; Engelmann, S.; Bläsing, O. E.; Raghavendra, A. S.; Westhoff, P. // Planta;Feb2006, Vol. 223 Issue 2, p359 

    Phosphoenolpyruvate carboxylase (PEPCase, EC is a key enzyme of C4 photosynthesis. It has evolved from ancestral non-photosynthetic (C3) isoforms and thereby changed its kinetic and regulatory properties. We are interested in understanding the molecular changes, as the C4 PEPCases were...

  • A new family of covalent inhibitors block nucleotide binding to the active site of pyruvate kinase. MORGAN, Hugh P.; WALSH, Martin J.; BLACKBURN, Elizabeth A.; WEAR, Martin A.; BOXER, Matthew B.; SHEN, Min; VEITH, Henrike; MCNAE, Iain W.; NOWICKI, Matthew W.; MICHELS, Paul A. M.; AULD, Douglas S.; FOTHERGILL-GILMORE, Linda A.; WALKINSHAW, Malcolm D. // Biochemical Journal;11/15/2012, Vol. 448 Issue 1, following p67 

    PYK (pyruvate kinase) plays a central role in the metabolism of many organisms and cell types, but the elucidation of the details of its function in a systems biology context has been hampered by the lack of specific high-affinity small-molecule inhibitors. High-throughput screening has been...

  • The combination of the expression of hexokinase 2 and pyruvate kinase M2 is a prognostic marker in patients with pancreatic cancer. OGAWA, HISATAKA; NAGANO, HIROAKI; KONNO, MASAMITSU; EGUCHI, HIDETOSHI; KOSEKI, JUN; KAWAMOTO, KOICHI; NISHIDA, NAOHIRO; COLVIN, HUGH; TOMOKUNI, AKIRA; TOMIMARU, YOSHITO; HAMA, NAOKI; WADA, HIROSHI; MARUBASHI, SHIGERU; KOBAYASHI, SHOGO; MORI, MASAKI; DOKI, YUICHIRO; ISHII, HIDESHI // Molecular & Clinical Oncology;2015, Vol. 3 Issue 3, p563 

    Metabolism may determine the biologically malignant behavior of pancreatic cancer. To investigate the significance and prognostic value of cancer metabolism in cancer patients, we investigated the expression of two key enzymes in anaerobic glycolysis, hexokinase 2 (HK2) and pyruvate kinase...

  • Efficacy of RNAi targeting of pyruvate kinase M2 combined with cisplatin in a lung cancer model. Guo, Wenhao; Zhang, Yu; Chen, Ting; Wang, Yongsheng; Xue, Jianxin; Zhang, Yonggang; Xiao, Wenjing; Mo, Xianming; Lu, You // Journal of Cancer Research & Clinical Oncology;Jan2011, Vol. 137 Issue 1, p65 

    Purpose: Pyruvate kinase isoenzyme M2 (PKM2) is a key enzyme in aerobic glycolysis; inhibition of PKM2 leads to the tumor growth inhibition. In this study, the effects of combined treatment with cisplatin (DDP) and a plasmid that expresses a short hairpin RNA (shRNA) targeting PKM2 on the growth...

  • Rescue of Pyruvate Kinase Deficiency in Mice by Gene Therapy Using the Human Isoenzyme. Meza, Nestor W.; Alonso-Ferrero, Maria E.; Navarro, Susana; Quintana-Bustamante, Oscar; Valeri, Antonio; Garcia-Gomez, Maria; Bueren, Juan A.; Bautista, Jose M.; Segovia, Jose C. // Molecular Therapy;Dec2009, Vol. 17 Issue 12, p2000 

    Human erythrocyte R-type pyruvate kinase deficiency (PKD) is a disorder caused by mutations in the PKLR gene that produces chronic nonspherocytic hemolytic anemia. Besides periodic blood transfusion and splenectomy, severe cases require bone marrow (BM) transplant, which makes this disease a...


Read the Article


Sign out of this library

Other Topics